Results Wire: US FDA Advisory Committee Supports Minor Changes to the Risk Evaluation and Mitigation Strategy of Alexion’s Soliris (Eculizumab) – NOV 18, 2014 (DSRM)
On Tuesday, November 18, 2014 the Drug Safety and Risk Management (DSRM) Advisory Committee supported keeping a Risk Evaluation and Mitigation Strategy (REMS) for Alexion’s Soliris (eculizumab) intact and making minor changes to it.